Ascentage Pharma Group International (OTCMKTS:ASPHF – Get Free Report)’s stock price was down 23.4% on Tuesday . The company traded as low as $7.50 and last traded at $7.7350. Approximately 3,556 shares changed hands during trading, a decline of 15% from the average daily volume of 4,200 shares. The stock had previously closed at $10.10.
Ascentage Pharma Group International Price Performance
The company’s fifty day moving average is $9.24 and its two-hundred day moving average is $7.75.
Ascentage Pharma Group International Company Profile
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation.
Recommended Stories
- Five stocks we like better than Ascentage Pharma Group International
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Keysight Technologies’ Surge: The Market Wakes Up to This AI Play
- Insider Trades May Not Tell You What You Think
- Is American Express the Credit Stock For a K-Shaped Economy?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Powering Up: How a Credit Upgrade Fuels Vistra’s AI Ambitions
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
